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Objective: Several small, 15-residue peptides that contain portions of the amino acid sequences of both cecropin A 
and melittin have previously been shown to have broad-spectrum antibacterial activities against aerobic micro- 
organisms, with no undesirable hemolytic properties. It would also be useful to know what effect these hybrid peptides 
have on anaerobic bacteria. 
Methods: The minimum inhibitory concentrations of one hybrid, CA(1-7)M(2-9)NHz, were compared with those of 
seven other antimicrobial agents against 11 1 clinical anaerobic strains; Bacferoides fragilis, 24 strains; other Bacteroides 
fragilis group, 14 strains; other Bacteroides species, 13 strains; Fusobacterium nucleaturn, six strains; Clostridium 
difficile, 22 strains; Clostridium perfringens, 10 strains, Propionibacferium spp., nine strains; and anaerobic cocci, 13 
strains. 
Results: Ninety per cent of strains belonging to the B. fragilis group, fusobacteria, propionibacteria and pepto- 
streptococci were inhibited by 4 mg/L CA(1-7)M(2-9)NH2, and the antimicrobial activity was approximately in the same 
range as that of chloramphenicol. 
Conclusion: This investigation showed that the antimicrobial spectrum of this cecropin-melittin hybrid also includes 
anaerobic organisms. 
Key words: Antimicrobial peptide, cecropin-melittin hybrid, anaerobic bacteria, antimicrobial susceptibility 
fragilis group, Clostridiurn spp., Fusobacteriurn nucleaturn 
and Peptostreptococcus spp. Treatment of anaerobic in- 
fections is often difficult, since many anaerobes are 
intrinsicdy resistant to many antimicrobial agents. 
Resistance against teracyches is widespread, and many 
clinically important anaerobes exhibit resistance to 
clindamycin and several p-lactarn agents as well. 
Resistance against cefoxitin, imipenem and metro- 
nidazole has been reported, although it is uncommon. 
Drugs commonly used in the treatment of anaerobic 
infections are p-lactam compocmds, clindamycin, 
metronidazole and chloramphenicol [5]. 
The increasing problem of antibiotic resistance 
among pathogenic bacteria requires the development 
of new antimicrobial agents. One line of investigation 
has involved the synthesis of hybrid peptides that 
contain portions of the amino acid sequences of 
two peptides with different antimicrobial properties, 
the cecropin-melittin hybrids [6,7]. The cecropins 
(e.g. cecropin A (one-letter abbreviations for amino 
INTRODUCTION 
The widespread use ofantimicrobial agents has, besides 
providing invaluable clinical achievements, resulted 
in the emergence of antimicrobial resistance among 
bacteria [I-31. Anaerobic bacteria are a Common cause 
of serious infections [4]. The anaerobic species which 
predominate in clinical infections include the Bacteroides 
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acids, with -NH2 indicating a C-terminal amide): 
KWKLFKKIEKVGQNIRDGIIKAGPAVAWGQAT 
QIAK-NH2) are antibacterial but do not, in general, 
affect higher eukaryotic cells [8]. In contrast, melittin 
(G IGAVLKVLTTGLPALIS WIKRKRQQ-NH 2 )  , a 
peptide found in the venom of the honeybee, Apis 
mellijera, is antibacterial, but also toxic to eukaryotic 
cells [8-101. One of these synthetic hybrids, CA(1- 
7)M(2-9)NH2, consists of the first seven amino acids 
of cecropin A linked to an eight amino acid sequence 
from the N-terminal region of melittin [ l l ] :  
KWUFKKIGAVLKVL-NH2. This peptide had the 
same or better antimicrobial activities than either parent 
peptide against a broad spectrum of Gram-positive and 
Gram-negative aerobic bacteria; it also had antimalarial 
activity, and it did not have the undesirable hemolytic 
properties of melittin. 
In previous investigations, the antibacterial pro- 
perties of these hybrid peptides have been assessed 
mostly with aerobic bacteria, but in this investigation, 
we have focused on the activities of CA(1-7)M 
(2-9)NHz against anaerobic bacteria. 
MATERIALS AND METHODS 
Peptide synthesis, purification, and analysis 
The peptide was synthesized by solid-phase methods, 
using Fmoc chemistry. It was purified by reverse-phase 
high-performance liquid chromatography, and its mass 
was verified by plasma desorption time-of-flight mass 
spectrometry [12]. 
The concentrations of CA(1-7)M(2-9)NH2 in 
aqueous solutions were estimated by absorption spectro- 
scopy at neutral pH and a wavelength of 280 nm, and 
using the molar absorption coefficient for tryptophan 
( E ~ S O =  5.6 x lo3 M-*cm-' ) ~ 3 1 .  
Antimicrobial susceptibility assays 
The antimicrobial activities of CA(1-7)M(2-9)NHz, 
piperacillin (Lederle Laboratories, Wayne, NJ), 
cefoxitin (Merck Sharp 81 Dohme, Rahway, NJ), 
imipenem (Merck Sharp & Dohme, Rahway, NJ), 
ciprofloxacin (Bayer AG, Wuppertal, Germany), 
clindamycin (Upjohn, Kalamazoo, MI), metronidazole 
(Rhone-Poulenc Rorer Inc., Collegeville, PA), and 
chloramphenicol (Parke-Davis Pharmaceutical Research 
Division, Warner Lambert Company, Ann Arbor, MI) 
against 11 1 anaerobic strains were determined. The 
strains were all clinical isolates collected at the Swedsh 
Institute for Infectious Disease Control, Stockholm, 
Sweden. The distribution of the strains were: Bacteroides 
fragilis, 24 strains; other Bacteroides fragilis group, 14 
strains (B.  un$ormis (n=5), B. ovatus ( n = 3 ) ,  B. distasonis 
(n=3), B. caccae (n=l) ,  B. thetaiotaomicron (n=1) and B. 
vulgatus (n= 1)); other Bacteroides spp. and Prevotella spp., 
13 strains (Prevotella bivia (n=4), Prevotella disiens (n=4), 
B. ureolyticus (n=2), B. ruminicola (n=1), B. splancnicus 
(n=1) and Bacteroides spp. (n=l)); Fusobacterium 
nucleatum, six strains; Clostridium dificile, 22 strains; 
C. pefringens, 10 strains; Propionibacterium spp., nine 
strains; Peptostreptococcus spp., eight strains (Pepto- 
streptococcus indolicus (n=2), Peptostreptococcus magnus 
(n= 2), Pep tos treptococcus asaccha roly ticus (n = 2), Pep to- 
streptococcus anaerobius (n= 1) and Peptostreptococcus prevotii 
(n=l)); and Streptococcus spp., five strains (Streptococcus 
intermedius (n=4) and Streptococcus mutans (n=l)). 
Identification was carried out by biochemical tests 
and gas-liquid chromatographic analysis according to 
Holdeman et a/ [14]. Antimicrobial susceptibility tests 
for piperacillin, cefoxitin, imipenem, ciprofloxacin, 
clindamycin, metronidazole and chloramphenicol were 
performed by the agar dilution method according 
to the National Committee for Clinical Laboratory 
Standards [ 151. Minimum inhibitory concentrations 
(MICs) of CA(1-7)M(2-9)NH2 were determined 
with the following modifications: fresh dilutions of 
CA(1-7)M(2-9)NH2 were prepared in sterile water, 
and final concentrations of the antimicrobial peptide 
in two-fold dilutions from 0.5 to 64 mg/L were pre- 
pared by incorporation of the substance into 1% 
agarose, type 1, low EEO (Sigma, St Louis, MO) in 
tryptic soy broth (Difco, Detroit, MI). A final inoculum 
of 105-106 C F U / d ,  prepared by dilution of 48 h 
cultures, was applied to the agar plates with a Steer's 
replicator. The reference strains were Escherickia coli 
ATCC 25922, Staphylococcus aureus ATCC 29213, B. 
fvagilis NCTC 9343, and C. petfringens ATCC 13124 
which were included in each run. Agar and agarose 
plates were incubated anaerobically in GasPak jars 
(BBL, MD) at 37°C for 48 h. MIC was defined as 
the lowest concentration that inhibited growth of 
organisms on the agar or agarose plates. 
RESULTS 
Ninety per cent of strains belonging to the B. jagilis 
group, fusobacteria, propionibacteria and pepto- 
streptococci were inhibited by 4 mg/L CA(1-7) 
M(2-9)NH2. The MIC values of CA(1-7)M(2-9)NH>, 
compared to those of piperadin, cefoxitin, imipenem, 
ciprofloxacin, clindamycin, metronidazole and chloram- 
phenicol, are shown in Table 1. The MIC values of 
CA(1-7)M(2-9)NH2 against the quality control strains 
tested were: E. coli ATCC 25922, 8 mg/L; Staphylo- 
coccus aureus ATCC 29213, 32 mg/L; B. fragilis NCTC 
9343, 8 mg/L; and C. pefringens ATCC 13124, 
64 mg/L. All reference strains were tested in five 
separate susceptibility runs, yielding identical results. 
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Table 1 Activities of CA( 1-7)M(2-9)NH2, piperacillin, cefoxitin, imipenem, ciprofloxacin, clindamycl n, metronidazole and 
chloramphenicol against 11 1 clinical anaerobic strains. MICso and MICso indicate the concentrations which inhibit the 
growth of 50% and 90% of the strains tested 
No. of Antimicrobial 
MIC (mg/L) 
strains agent Range MICso MIC9o Microorganism 
Other B. fragilis group 
Bacteroides sppa 
and Prevotella spp 
Fusobarteritim nucleatum 
Clostridium df ic i le  
Bacteroides jag& 24 
14 
13 
6 
22 
10 
Propionibacterium spp. 9 
CA(1-7)M(2-9)NH* 
Piperacillin 
Cefoxitin 
Imipenem 
Ciprofloxacin 
Clindamy cin 
Metronidazole 
Chloramphenicol 
CA(1-7)M(2-9)NH* 
Piperacillin 
Cefoxitin 
Imipenem 
Ciprofloxacin 
Clindamycin 
Metronidazole 
Chloramphenicol 
CA(1-7)M(2-9)NHz 
Piperacillin 
Cefoxitin 
Imipenem 
Ciprofloxacin 
Clindamy cin 
Metronidazole 
Chloramphenicol 
CA(1-7)M(2-9)NH* 
Piperacillin 
Cefoxitin 
Imipenem 
Ciprofloxacin 
Clindamy cin 
Metronidazole 
Chloramphenicol 
CA(1-7)M(2-9)NH2 
Piperacillin 
Cefoxitin 
Imipenem 
Ciprofloxacin 
Clindamycin 
Metronidazole 
Chloramphenicol 
CA(1-7)M(2-9)NH* 
Piperacillin 
Cefoxitin 
Imipenem 
Ciprofloxacin 
Clindamycin 
Metronidazole 
Chloramphenicol 
CA(1-7)M(2-9)NHz 
Piperacillin 
Cefoxitin 
2-8 
2-256 
4-16 
0.064-0.5 
2-8 
0.032-2 
0.5-1 
4 
2-4 
4 to >lo24 
4-32 
0.064-1 
2 to >16 
0.032-8 
0.5-1 
4 
2-32 
0.064-4 
0.125-4 
0.016-0.25 
0.064 to >16 
0.016-0.25 
0.5-1 
4 
2-4 
0.032-1 
0.25-16 
0.008-0.064 
0.016-2 
0.016-0.016 
0.5-4 
4 
0.5-32 
0.125-32 
32-128 
2-8 
4-16 
0.125 to >256 
0.125-0.5 
0.5-4 
16-32 
0.016-2 
0.5-1 
0.125-0.25 
0.125-0.5 
0.008-1 
1-1 
4-8 
2-4 
0.125-0.25 
0.125-0.5 
4 
8 
8 
0.125 
4 
0.5 
0.5 
4 
4 
8 
8 
0.125 
2 
0.5 
1 
4 
4 
0.5 
1 
0.032 
4 
0.016 
1 
4 
2 
0.064 
0.5 
0.032 
1 
0.016 
2 
4 
2 
4 
64 
8 
8 
4 
0.125 
2 
32 
0.064 
0.5 
0.25 
0.25 
0.125 
I 
4 
4 
0.25 
0.25 
4 
128 
16 
0.125 
8 
1 
1 
4 
4 
1024 
32 
0.5 
8 
2 
1 
4 
8 
4 
1 
0.25 
16 
0.016 
1 
4 
4 
1 
16 
0.064 
2 
0.016 
2 
4 
16 
32 
128 
8 
16 
128 
0.5 
4 
32 
1 
1 
0.25 
0.5 
0.25 
1 
8 
4 
0.25 
0.5 
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Table 1 continued 
MIC (mg/L) 
No. of Antimicrobial 
Microorganism strains agent Range MIC5o MIC9o 
Propioriibacterium spp. Imipenem 0.032-0.064 0.032 0.064 
Ciprofloxacin 0.25-0.5 0.5 0.5 
Clindamycin 0.016-0.064 0.016 0.064 
Metronidazolc 32 to >64 264 >(I4 
Chloramphenicol 1 1 1 
Pep tos treptocorcus spp. 8 CA(1-7)M(2-9)NHz 
Piperacihn 
Cefoxitin 
Irnipenern 
Ciprofloxacin 
Clindamycin 
Metronidazole 
Chloramphenicol 
-I CA(1-7)M(2-9)NHz 
Piperacillin 
Cefoxitin 
Imipenem 
Ciprofloxacin 
Clindamycin 
Metronidazole 
Chloramphenicol 
2-4 
0.01 6-0.25 
0.25-8 
0.016-0.064 
1-8 
0.0641 
0.25-8 
1-8 
2 to >64 
0.064-0.25 
2-8 
0.016-0.032 
1-4 
0.064 
0.5-4 
4- 8 
2 
0.064 
0.25 
0.01 6 
2 
0.064 
4 
4 
4 
0.064 
4 
0.032 
1 
0.064 
4 
4 
4 
0.25 
8 
0.064 
8 
1 
8 
8 
> 64 
(3.2.5 
8 
0.032 
4 
0 064 
4 
8 
DISCUSSION 
The activity of CA(1-7)M(2-9)NHz against anaerobic 
organisms has not been extensively tested, although 
there is one report in the literature on the activity of 
several structural analogues of this peptide against one 
strain each of B. jagil is  and C. perjiringens, and four 
strains of Streptococcus [ 161. The present investigation 
verifies that the range of antimicrobial activities of 
cecropin-melittin hybrid peptides is not restricted to 
aerobic microorganisms, but also includes several Gram- 
negative and Gram-positive anaerobic organisms. 
One hypothesis of the mechanism of action of 
the recently discovered peptide antibiotics, and the 
cecropin-melittin hybrids, is that they form ion 
channels in the bacterial cytoplasmic membrane, which 
disrupt the ionic homeostasis of the bacterial cell and 
lead to cell death [17]. However, the abhty of this 
peptide to form ion channels is not yet established. 
Alternative mechanisms that have been proposed for 
these peptides are a detergent-like activity on the 
cytoplasmic membrane, and the stimulation of auto- 
lysis. The results reported here do not show great 
differences between the activities of CA( 1-7)M 
(2-9)NHz on Gram-positive and on Gram-negative 
organisms, as might be expected if the mechanism 
involved the stimulation of autolysis [18]. The absence 
of differences between the activities on Gram-positive 
and Gram-negative organisms indicates that the outer 
membrane of Gram-negative anaerobes does not serve 
as a barrier to CA(1-7)M(2-9)NHz, as it does for the 
larger cecropin peptides with Gram-negative aerobes 
The antimicrobial activity of CA(1-7)M(2-9)NWz 
against the clinical isolates tested in the present study is 
hard to interpret, due to the lack of pharmacokinetic 
studies on cecropin-melittin hybrid peptides. However, 
the results, especially for the B. fragilis group, which are 
particularly important pathogens with increasing 
resistance problems, is encouraging enough to warrant 
further studes on these antimicrobial peptides. 
~ 9 1 .  
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